Categories: CancerNews

Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare
  • Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET

SOUTH SAN FRANCISCO, Calif., July 26, 2023 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report second quarter 2023 financial results on Wednesday, August 2, 2023, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 PM Pacific Time/5:00 PM Eastern Time.

Listen-Only Webcast
The listen-only webcast will be made available on the Company’s website at www.allogene.com under the Investors tab in the News and Events section. A replay will be available on the Company’s website for approximately 30 days.

Conference Call Registration
If you would like the option to ask a question on the conference call, please use this link to register. Upon registering for the conference call, you will receive a personal PIN to access the call.

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:
Christine Cassiano
Chief Communications Officer
(714) 552-0326
Christine.Cassiano@allogene.com

Staff

Recent Posts

Scryb Inc. Provides Early Warning Update on Holdings In Cybeats Technologies Corp.

Toronto, Ontario--(Newsfile Corp. - August 8, 2025) - Scryb Inc. (CSE: SCYB) (OTC Pink: SCYRF)…

3 hours ago

BioNxt Solutions Announces Closing of Final Tranche of Oversubscribed Convertible Debenture Unit Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED…

3 hours ago

xCures Achieves Fully Functional IAS Solution

The fully operational Individual Access Services (IAS) solution under TEFCA will deliver on the promise…

6 hours ago

Pharmacy Profiles to provide credential verification services for McKesson’s Health Mart pharmacies

WASHINGTON, Aug. 8, 2025 /PRNewswire/ -- Pharmacy Profiles, the trusted source for pharmacist identity and…

6 hours ago

DentScribe CoPilot Is Changing the Game for Mom-Dentists: SOAP Notes Now Fuel Profit, Not Burden

SUNNYVALE, Calif., Aug. 8, 2025 /PRNewswire/ -- For busy mom-dentists, charting SOAP notes used to…

6 hours ago

Memorial Healthcare System Deploys Population Health Technology to Drive Medication Adherence

HOLLYWOOD, Fla. and ARLINGTON, Va., Aug. 8, 2025 /PRNewswire/ -- Memorial Healthcare System has launched…

6 hours ago